Milk Exosome-Liposome Hybrid Delivers Oral Semaglutide with 8.7% Bioavailability
A hybrid vesicle combining milk exosomes with functionalized liposomes achieved 2.4-fold better semaglutide loading and 8.7% oral bioavailability by adapting its surface properties to overcome sequential gut absorption barriers.
Quick Facts
What This Study Found
Milk exosome-liposome hybrid vesicles (mExos@DSPE-Hyd-PMPC) achieved 2.4× semaglutide encapsulation efficiency over natural exosomes and 8.7% oral bioavailability through pH-responsive surface adaptation that overcomes sequential gut absorption barriers.
Key Numbers
Hybrid vesicles significantly improved oral bioavailability compared to exosomes or liposomes alone. Published in ACS Nano.
How They Did This
Hybrid vesicles created by fusing functionalized liposomes (containing pH-sensitive hydrazone-linked zwitterionic polymer) with natural milk exosomes. Characterized for semaglutide loading, mucus penetration, epithelial barrier crossing, and oral bioavailability in animal models.
Why This Research Matters
Oral peptide delivery is the holy grail of drug delivery — most peptide drugs require injection. Achieving 8.7% oral bioavailability for semaglutide using a milk-derived natural carrier is a major step toward needle-free peptide therapies.
The Bigger Picture
The oral semaglutide tablet (Rybelsus) currently achieves about 1% bioavailability and requires strict fasting. An 8.7% bioavailability platform using safe, milk-derived exosomes could dramatically improve oral peptide drug delivery across many therapeutic areas — not just GLP-1 agonists.
What This Study Doesn't Tell Us
Animal study — human gastrointestinal conditions differ from the models used. Manufacturing scalability of exosome-liposome hybrids is uncertain. Long-term stability and shelf life haven't been assessed. Regulatory pathway for milk exosome-based drug delivery is unclear.
Questions This Raises
- ?Could this delivery platform work for other peptide drugs beyond semaglutide?
- ?How does the 8.7% bioavailability compare to current oral semaglutide formulations in equivalent animal models?
- ?Can milk exosome-liposome hybrid production be scaled for commercial pharmaceutical manufacturing?
Trust & Context
- Key Stat:
- 8.7% oral bioavailability For semaglutide delivered via milk exosome-liposome hybrid vesicles — significantly higher than current oral peptide formulations
- Evidence Grade:
- Preliminary evidence from an animal study demonstrating proof-of-concept for the delivery platform. No human pharmacokinetic studies have been conducted.
- Study Age:
- Published in 2024; represents cutting-edge oral peptide drug delivery research.
- Original Title:
- Milk Exosome-Liposome Hybrid Vesicles with Self-Adapting Surface Properties Overcome the Sequential Absorption Barriers for Oral Delivery of Peptides.
- Published In:
- ACS nano, 18(32), 21091-21111 (2024)
- Authors:
- Xiao, Peifu, Wang, Hanxun, Liu, Hongbing, Yuan, Haoyang, Guo, Chen, Feng, Yupeng, Qi, Pan, Yin, Tian, Zhang, Yu, He, Haibing, Tang, Xing, Gou, Jingxin
- Database ID:
- RPEP-09560
Evidence Hierarchy
Frequently Asked Questions
Why is it so hard to take peptide drugs like semaglutide by mouth?
Peptide drugs are proteins that get broken down by stomach acid and digestive enzymes, just like food proteins. Even if they survive digestion, they struggle to cross the intestinal lining because they're too large and charged. That's why most peptide drugs require injection — only about 1% of an oral dose typically reaches the bloodstream.
What are milk exosomes?
Exosomes are tiny natural vesicles (nano-sized bubbles) that cells release for communication. Milk naturally contains exosomes that can survive digestion and cross the gut barrier — a property evolved to deliver nutrients and signaling molecules from mother to infant. Researchers are harnessing this natural ability to deliver drugs.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09560APA
Xiao, Peifu; Wang, Hanxun; Liu, Hongbing; Yuan, Haoyang; Guo, Chen; Feng, Yupeng; Qi, Pan; Yin, Tian; Zhang, Yu; He, Haibing; Tang, Xing; Gou, Jingxin. (2024). Milk Exosome-Liposome Hybrid Vesicles with Self-Adapting Surface Properties Overcome the Sequential Absorption Barriers for Oral Delivery of Peptides.. ACS nano, 18(32), 21091-21111. https://doi.org/10.1021/acsnano.4c02560
MLA
Xiao, Peifu, et al. "Milk Exosome-Liposome Hybrid Vesicles with Self-Adapting Surface Properties Overcome the Sequential Absorption Barriers for Oral Delivery of Peptides.." ACS nano, 2024. https://doi.org/10.1021/acsnano.4c02560
RethinkPeptides
RethinkPeptides Research Database. "Milk Exosome-Liposome Hybrid Vesicles with Self-Adapting Sur..." RPEP-09560. Retrieved from https://rethinkpeptides.com/research/xiao-2024-milk-exosomeliposome-hybrid-vesicles
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.